Area of research
Physiology · Immunology and Allergy
Research interest
Research focused on Asthma and Mepolizumab, with related work in Allergy, B-cell activating factor, Immunology. Notable publications include 'Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the...', 'Overexpression of the Cytokine BAFF and Autoimmunity Risk', and 'EAACI Biologicals Guidelines—Recommendations for severe asthma'.
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study
Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
Profiling Blood Hypereosinophilia in Patients on Dupilumab Treatment for Respiratory Conditions: A Real-Life Snapshot
Optimising care for chronic rhinosinusitis with nasal polyps and asthma in multimorbid patients: a multidisciplinary Delphi consensus
Reply to Correspondence: The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An <scp>EAACI</scp> Position Paper
The epithelial barrier theory and its associated diseases
The Bronchodilator and Anti‐Inflammatory Effect of Long‐Acting Muscarinic Antagonists in Asthma: An <scp>EAACI</scp> Position Paper
Severely compromised supply of patch test allergens in Europe hampers adequate diagnosis of occupational and non‐occupational contact allergy. A European Society of Contact Dermatitis (<scp>ESCD</scp>), European Academy of Allergy and Clinical Immunology (<scp>EAACI</scp>), European Academy of Dermatology and Venereology (<scp>EADV</scp>) task forces ‘Contact Dermatitis’ and ‘Occupational Skin Disease’ position paper
Asthma remission one, none and one-hundred thousand: the relevance of the patient’s view
Obituary: Professor Marcus Maurer, Berlin, Germany
Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study
<scp>EAACI</scp> guidelines on the diagnosis of <scp>IgE</scp>‐mediated food allergy
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An <scp>EAACI</scp> position paper
Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air<sup>®</sup>approach
Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The <scp>ARIA‐EAACI</scp> approach – ARIA‐EAACI Task Force Report
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study
Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
<scp>UCRAID</scp> (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan
A concept for integrated care pathways for atopic dermatitis—A GA<sup>2</sup>LEN ADCARE initiative
From MASK-air and SILAM to CATALYSE (Climate Action To Advance HeaLthY Societies in Europe)
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life
The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis
Physical exercise, immune response, and susceptibility to infections—current knowledge and growing research areas
Comparison of rhinitis treatments using <scp>MASK</scp>‐air® data and considering the minimal important difference
Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The <scp>MASK</scp>‐air® longitudinal study
Cutoff Values of MASK-air Patient-Reported Outcome Measures
Development and Validation of an Electronic Daily Control Score for Asthma (e-DASTHMA)
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines